REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy.

The REV3L gene, encoding the catalytic subunit of human polymerase zeta, plays a significant role in the cytotoxicity, mutagenicity, and chemoresistance of certain tumors. However, the role of REV3L in regulating the sensitivity of glioma cells to chemotherapy remains unknown. In this study, we investigated the expression of the REV3L gene in 10 normal brain specimens and 30 human glioma specimens and examined the value of REV3L as a potential modulator of cellular response to various DNA-damaging agents. Reverse transcriptase PCR/real-time PCR analysis revealed that REV3L was overexpressed in human gliomas compared with normal brain tissues. A glioma cell model with stable overexpression of REV3L was used to probe the role of REV3L in cisplatin treatment; upregulation of REV3L markedly attenuated cisplatin-induced apoptosis of the mitochondrial apoptotic pathway. We therefore assessed the REV3L-targeted treatment modality that combines suppression of REV3L expression using RNA interference (RNAi) with the cytotoxic effects of DNA-damaging agents. Downregulation of REV3L expression significantly enhanced the sensitivity of glioma cells to cisplatin, as evidenced by the increased apoptosis rate and marked alterations in the anti-apoptotic proteins B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-xl) and proapoptotic Bcl-2-associated x protein (Bax) expression levels, and reduced mutation frequencies in surviving glioma cells. These results suggest that REV3L may potentially contribute to gliomagenesis and play a crucial role in regulating cellular response to the DNA cross-linking agent cisplatin. Our findings indicate that RNAi targeting REV3L combined with chemotherapy has synergistic therapeutic effects on glioma cells, which warrants further investigation as an effective novel therapeutic regimen for patients with this malignancy.

[1]  A. Shervington,et al.  Chemoresistance in gliomas , 2008, Molecular and Cellular Biochemistry.

[2]  L. Chin,et al.  Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.

[3]  W. Pardridge.  shRNA and siRNA delivery to the brain. , 2007, Advanced drug delivery reviews.

[4]  Anna Moore,et al.  In vivo imaging of siRNA delivery and silencing in tumors , 2007, Nature Medicine.

[5]  John J. Rossi,et al.  Strategies for silencing human disease using RNA interference , 2007, Nature Reviews Genetics.

[6]  A. Lehmann.  Translesion synthesis in mammalian cells. , 2006, Experimental cell research.

[7]  G. Barger,et al.  In vitro Drug Response and Molecular Markers Associated with Drug Resistance in Malignant Gliomas , 2006, Clinical Cancer Research.

[8]  A. Aigner,et al.  RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. , 2006, Human gene therapy.

[9]  P. Lambin,et al.  Lysine 63-Polyubiquitination Guards against Translesion Synthesis–Induced Mutations , 2006, PLoS genetics.

[10]  G. Palù,et al.  Clinical trials of gene therapy, virotherapy, and immunotherapy for malignant gliomas , 2006, Cancer Gene Therapy.

[11]  S. Howell,et al.  Human REV1 Modulates the Cytotoxicity and Mutagenicity of Cisplatin in Human Ovarian Carcinoma Cells , 2006, Molecular Pharmacology.

[12]  H. Cheung,et al.  Inactivation of human MAD2B in nasopharyngeal carcinoma cells leads to chemosensitization to DNA-damaging agents. , 2006, Cancer research.

[13]  P. Cartron,et al.  The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. , 2006, Cancer research.

[14]  Xinbin Chen,et al.  DNA Polymerase η, the Product of the Xeroderma Pigmentosum Variant Gene and a Target of p53, Modulates the DNA Damage Checkpoint and p53 Activation , 2006, Molecular and Cellular Biology.

[15]  Ju-Hyung Woo,et al.  Increased Expression of Mitotic Checkpoint Genes in Breast Cancer Cells with Chromosomal Instability , 2006, Clinical Cancer Research.

[16]  S. Howell,et al.  DNA Polymerase ζ Accounts for the Reduced Cytotoxicity and Enhanced Mutagenicity of Cisplatin in Human Colon Carcinoma Cells That Have Lost DNA Mismatch Repair , 2006, Clinical Cancer Research.

[17]  D. Keppler,et al.  ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. , 2005, Cancer research.

[18]  H. Saya,et al.  Multiple Roles of Vertebrate REV Genes in DNA Repair and Recombination , 2005, Molecular and Cellular Biology.

[19]  S. Howell,et al.  Suppression of hREV1 Expression Reduces the Rate at Which Human Ovarian Carcinoma Cells Acquire Resistance to Cisplatin , 2005, Molecular Pharmacology.

[20]  M. Albertella,et al.  The overexpression of specialized DNA polymerases in cancer. , 2005, DNA repair.

[21]  L. Deangelis,et al.  Chemotherapy for brain tumors--a new beginning. , 2005, The New England journal of medicine.

[22]  Xun Hu,et al.  Down-regulation of DNA polymerases κ, η, ι, and ζ in human lung, stomach, and colorectal cancers , 2005 .

[23]  S. Howell,et al.  DNA Polymerase ζ Regulates Cisplatin Cytotoxicity, Mutagenicity, and The Rate of Development of Cisplatin Resistance , 2004, Cancer Research.

[24]  K. Ohkawa,et al.  Chemotherapeutic agents that induce mitochondrial apoptosis. , 2004, Current cancer drug targets.

[25]  I. Pollack,et al.  Cytokine gene therapy for malignant glioma , 2004, Expert opinion on biological therapy.

[26]  M. Yamaizumi,et al.  Multiple roles of Rev3, the catalytic subunit of polζ in maintaining genome stability in vertebrates , 2003, The EMBO journal.

[27]  S. Orrenius,et al.  Role of mitochondria in toxic cell death. , 2002, Toxicology.

[28]  J. Zentner,et al.  Brain-tumour drug resistance: the bare essentials. , 2002, The Lancet. Oncology.

[29]  N. de Wind,et al.  Involvement of Mouse Rev3 in Tolerance of Endogenous and Exogenous DNA Damage , 2002, Molecular and Cellular Biology.

[30]  G. Reifenberger,et al.  The WHO Classification of Tumors of the Nervous System , 2002, Journal of neuropathology and experimental neurology.

[31]  M. Tagawa,et al.  DNA polymerase kappa, implicated in spontaneous and DNA damage-induced mutagenesis, is overexpressed in lung cancer. , 2001, Cancer research.

[32]  M. Bredel.  Anticancer drug resistance in primary human brain tumors , 2001, Brain Research Reviews.

[33]  S. Srinivasula,et al.  Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. Negrini,et al.  Alternative splicing, genomic structure, and fine chromosome localization of REV3L , 1999, Cytogenetic and Genome Research.

[35]  P E Gibbs,et al.  A human homolog of the Saccharomyces cerevisiae REV3 gene, which encodes the catalytic subunit of DNA polymerase zeta. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[36]  W. Cavenee,et al.  Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[37]  W. Xiao,et al.  Identification, chromosomal mapping and tissue-specific expression of hREV3 encoding a putative human DNA polymerase zeta. , 1998, Carcinogenesis.

[38]  S. Piantadosi,et al.  Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  C. Lawrence,et al.  Thymine-Thymine Dimer Bypass by Yeast DNA Polymerase ζ , 1996, Science.

[40]  W. Xiao,et al.  Eukaryotic DNA damage tolerance and translesion synthesis through covalent modifications of PCNA , 2008, Cell Research.

[41]  Robert Rosenberg,et al.  Expression of the mitotic checkpoint gene MAD2L2 has prognostic significance in colon cancer , 2007, International journal of cancer.

[42]  K. Kajiwara,et al.  The error-prone DNA polymerase zeta catalytic subunit (Rev3) gene is ubiquitously expressed in normal and malignant human tissues. , 2001, International journal of oncology.

[43]  C. Lawrence,et al.  DNA polymerase zeta and the control of DNA damage induced mutagenesis in eukaryotes. , 1996, Cancer surveys.

[44]  J. Mccormick,et al.  The HPRT Gene as a Model System for Mutation Analysis , 1996 .

[45]  G. Pfeifer.  Technologies for Detection of DNA Damage and Mutations , 1996, Springer US.